FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Multiple Violations at Guyer Institute

[ Price : $8.95]

FDA warns Guyer Institute of Molecular Medicine about CGMP and other violations in its production of compounded drugs.

Pfizer Covid Pill Reduces Hospitalization/Death: Study

[ Price : $8.95]

Pfizer says it will submit new data for its Covid-19 oral antiviral Paxlovid (ritonavir) that showed the drug significantly reduce...

Upton, DeGette Introduce Cures 2.0

[ Price : $8.95]

Reps. Upton and DeGette introduce their bipartisan Cures 2.0 legislation to create an Advanced Research Projects Agency-Health to ...

PhRMA Strategies to Enhance Trial Diversity

[ Price : $8.95]

PhRMA and Deloitte release a report with strategies for increasing clinical trial diversity.

FDA Terminates Kalidindi Debarment

[ Price : $8.95]

Federal Register notice: FDA issues an order granting special termination of the debarment involving Sanyasi Raju Kalidindi.

Qinlock Regulatory Review Period Determined

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Deciphera Pharmaceuticals Q...

China Valsartan API Firm Resolves GMP Issues

[ Price : $8.95]

FDA issues a close-out letter citing resolved GMP issues at Zhejiang Huahai Pharmaceutical Co., Zhejiang, China, an active pharmac...

HHS Reverses FDA Policy on Lab-Developed Tests

[ Price : $8.95]

HHS withdraws a Trump Administration policy that directed FDA not to enforce premarket review requirements for laboratory develope...

CBER Warns Firm on Cellular Product

[ Price : $8.95]

CBER sends NYC Regenerative Medicine an untitled letter over its Web site and Facebook page that markets its cellular product deri...

Revised Guide on Covid Test Transport Media

[ Price : $8.95]

FDA posts a revised guidance entitled Enforcement Policy for Viral Transport Media During the Coronavirus Disease 2019 Public Heal...